We specialize in innovative research and application of advanced technologies such as mucosal immune vaccines, oncolytic viruses, gene therapy, antiviral drug discovery, and viral vectors. Our vaccine pipeline focuses on mucosal immune vaccines, establishing the first line of defense against infection for the body, with a significant competitive advantage. We also have strategic layouts in oncolytic viruses and gene therapy, particularly excelling in the targeting of gene delivery and the controllability of viral vectors.

The company's core team is composed of overseas-educated PhDs from Chinese and American teams, as well as multiple professionals in fields such as virology and molecular biology, possessing original innovative capabilities. The company places great emphasis on self-research and development  as well as  the accumulation of intellectual property protection. Currently, over 70 patent applications have been filed, with over 10 of them being international PCT applications. The patents have previously won the Excellent Award at the 23rd China Patent Awards.

The R&D center is equipped with professional BSL-2 negative pressure laboratories and animal experiment platforms, establishing a quality management system compliant with ISO 9001 standards. Through advanced technologies such as in vivo and in vitro efficacy evaluation systems, pseudovirus construction, high-throughput screening of antiviral drugs, and live imaging, along with P2 virus animal infection models, the center conducts efficacy evaluations for oncolytic viruses, vaccines, and antiviral drugs. It provides various CRO services to innovative drug development companies, research institutions, and other entities.